Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bmcl.2020.127667 http://scihub22266oqcxt.onion/10.1016/j.bmcl.2020.127667 33160024!7640924!33160024     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33160024&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Bioorg+Med+Chem+Lett 2021 ; 31 (?): 127667 Nephropedia Template TP {{tp|p=33160024|t=2021. Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2 |pdf=|usr=}}{{33160024}} gab.com Text Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2 JO: Bioorg Med Chem Lett http://www.kidney.de/pget.php?&tw=1&pmid=33160024 #FOAvip Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) continues to spread worldwide, with 25 million confirmed cases and 800 thousand deaths. Effective treatments to target SARS-CoV-2 are urgently needed. In the present study, we have identified a class of cyclic sulfonamide derivatives as novel SARS-CoV-2 inhibitors. Compound 13c of the synthesized compounds exhibited robust inhibitory activity (IC(50) = 0.88 muM) against SARS-CoV-2 without cytotoxicity (CC(50) > 25 muM), with a selectivity index (SI) of 30.7. In addition, compound 13c exhibited high oral bioavailability (77%) and metabolic stability with good safety profiles in hERG and cytotoxicity studies. The present study identified that cyclic sulfonamide derivatives are a promising new template for the development of anti-SARS-CoV-2 agents. Twit Text FOAVip Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2 ????Bioorg Med Chem Lett http://www.kidney.de/pget.php?&tw=1&pmid=33160024 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33160024 #FOAvip English Wikipedia <ref>{{Cite pmid|33160024}}</ref> Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2 #MMPMID33160024 Shin YS; Lee JY; Noh S; Kwak Y; Jeon S; Kwon S; Jin YH; Jang MS; Kim S; Song JH; Kim HR; Park CM Bioorg Med Chem Lett 2021[Jan]; 31 (?): 127667 PMID33160024show ga Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) continues to spread worldwide, with 25 million confirmed cases and 800 thousand deaths. Effective treatments to target SARS-CoV-2 are urgently needed. In the present study, we have identified a class of cyclic sulfonamide derivatives as novel SARS-CoV-2 inhibitors. Compound 13c of the synthesized compounds exhibited robust inhibitory activity (IC(50) = 0.88 muM) against SARS-CoV-2 without cytotoxicity (CC(50) > 25 muM), with a selectivity index (SI) of 30.7. In addition, compound 13c exhibited high oral bioavailability (77%) and metabolic stability with good safety profiles in hERG and cytotoxicity studies. The present study identified that cyclic sulfonamide derivatives are a promising new template for the development of anti-SARS-CoV-2 agents. |*Drug Discovery[MESH] |Animals[MESH] |Antiviral Agents/chemical synthesis/chemistry/*pharmacology[MESH] |COVID-19 Drug Treatment[MESH] |Cell Line[MESH] |Chlorocebus aethiops[MESH] |Cricetulus[MESH] |Dogs[MESH] |Dose-Response Relationship, Drug[MESH] |Humans[MESH] |Mice[MESH] |Microbial Sensitivity Tests[MESH] |Molecular Structure[MESH] |Rats[MESH] |SARS-CoV-2/*drug effects[MESH] |Structure-Activity Relationship[MESH]Discovery of cyclic sulfonamide derivatives as potent inhibitors of SA(epmc).pdf DeepDyve Pubget Overpricing